Stubborn headwinds in the generic-drug markets are forcing the company to restructure operations.
The field expanded into a new therapeutic area, and fell back into a bitter dispute over intellectual property.
The post-IPO blues hit pretty hard last month.
The good news keeps rolling in for this Belgian pharma.
Was last month a turning point in a not-so-good year for shareholders?
The company rebounded after remedying an embarrassing regulatory gaffe.
The clinical-stage biopharma announced promising data at a major conference.
The pharmaceutical pipeline shined, and the business doubled its cash position.
The business reported an upbeat update, but something got lost in translation on Wall Street.
The immune cells live up to their name in natural settings, but engineered therapies have delivered mixed results in clinical trials.
These businesses are turning wasteful consumption into long-term value for shareholders and the planet.
Wall Street might be overlooking these intriguing investing opportunities.
New legislation requires renewables to generate 70% of the state's electricity by 2030.
The rise of renewables, a surprising resilience in nuclear power, and the fall of coal were all clearly evident in April power generation data.
The pharmaceutical company increased guidance for its blockbuster-in-waiting.
Whether you're reading this from a hammock or planning for retirement years from now, these three income stocks can help you to build wealth.
A mid-stage trial failure has investors questioning the company's approach.
The company cleared up an issue with the FDA.
The coal producer sports an eye-popping 12.6% distribution yield, but does coal belong in your portfolio?
A high-profile analyst questioned the company's recent FDA approval.